|
| 36795286 | Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction. | J Cardiovasc Transl Res | 2024 |
| 37964408 | Growth differentiation factor-15 and the effect of empagliflozin in heart failure: Findings from the EMPEROR program. | Eur J Heart Fail | 2024 |
| 37715769 | Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced. | JACC Heart Fail | 2024 |
| 38069997 | Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper. | JACC Heart Fail | 2024 |
| 38006196 | Cell Therapy Improves Quality-of-Life in Heart Failure: Outcomes From a Phase III Clinical Trial. | Stem Cells Transl Med | 2024 |
| 38059343 | European Society of Cardiology Core Curriculum for cardio-oncology. | Eur J Heart Fail | 2024 |
| 37933184 | Sacubitril/valsartan compared to ramipril in high-risk post-myocardial infarction patients stratified according to use of mineralocorticoid receptor antagonists: Insight from the PARADISE MI trial. | Eur J Heart Fail | 2024 |
| 38037709 | Effects of empagliflozin on collagen biomarkers in patients with heart failure: Findings from the EMPEROR trials. | Eur J Heart Fail | 2024 |
| 37820896 | Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial. | J Card Fail | 2024 |
| 37972677 | Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure. | Am Heart J | 2024 |
| 37814928 | Efficacy of finerenone in patients with type 2 diabetes, chronic kidney disease and altered markers of liver steatosis and fibrosis: A FIDELITY subgroup analysis. | Diabetes Obes Metab | 2024 |
| 36342827 | Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled. | Circulation | 2023 |
| 37634520 | Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial. | Lancet | 2023 |
| 37558088 | Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial. | J Card Fail | 2023 |
| 37905371 | Incidence, risk assessment and prevention of sudden cardiac death in cardiomyopathies. | Eur J Heart Fail | 2023 |
| 37905361 | Early changes in renal function during rapid up-titration of guideline-directed medical therapy following an admission for acute heart failure. | Eur J Heart Fail | 2023 |
| 37592272 | Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial. | Cardiovasc Diabetol | 2023 |
| 37661847 | Associations between baseline heart rate and blood pressure and time to events in heart failure with reduced ejection fraction patients: Data from the QUALIFY international registry. | Eur J Heart Fail | 2023 |
| 37623428 | Renal function and decongestion with acetazolamide in acute decompensated heart failure: the ADVOR trial. | Eur Heart J | 2023 |
| 37621153 | Blinded Withdrawal of Long-Term Randomized Treatment With Empagliflozin or Placebo in Patients With Heart Failure. | Circulation | 2023 |
| 37994632 | Plain language summary of the EMPEROR-Preserved study looking at the effect of empagliflozin in patients with heart failure with preserved ejection fraction, with and without diabetes. | Future Cardiol | 2023 |
| 37990135 | Rationale and design of the ESC Heart Failure III Registry - Implementation and discovery. | Eur J Heart Fail | 2023 |
| 37649316 | Hospitalization for acute heart failure during non-working hours impacts on long-term mortality: the REPORT-HF registry. | ESC Heart Fail | 2023 |
| 38048573 | Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis. | Ann Intern Med | 2023 |
| 37940229 | Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure. | J Am Coll Cardiol | 2023 |
| 37644114 | Non-steroidal mineralocorticoid receptor antagonists in heart failure. | Nat Rev Cardiol | 2023 |
| 37728907 | Repurposing the β3-Adrenergic Receptor Agonist Mirabegron in Patients With Structural Cardiac Disease: The Beta3-LVH Phase 2b Randomized Clinical Trial. | JAMA Cardiol | 2023 |
| 37728038 | Non-cardiac comorbidities and intensive up-titration of oral treatment in patients recently hospitalized for heart failure: Insights from the STRONG-HF trial. | Eur J Heart Fail | 2023 |
| 37678961 | Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry. | JACC Heart Fail | 2023 |
| 37973338 | Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study. | Lancet Glob Health | 2023 |
| 37565377 | Decongestion strategies in patients presenting with acutely decompensated heart failure: A worldwide survey among physicians. | Eur J Heart Fail | 2023 |
| 37532426 | Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3. | J Am Coll Cardiol | 2023 |
| 37461163 | Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension. | Eur J Heart Fail | 2023 |
| 37257948 | Uptitrating Treatment After Heart Failure Hospitalization Across the Spectrum of Left Ventricular Ejection Fraction. | J Am Coll Cardiol | 2023 |
| 37191154 | Sex-specific analysis of the rapid up-titration of guideline-directed medical therapies after a hospitalization for acute heart failure: Insights from the STRONG-HF trial. | Eur J Heart Fail | 2023 |
| 37021198 | Prolonged cardiac monitoring for stroke prevention: A systematic review and meta-analysis of randomized-controlled clinical trials. | Eur Stroke J | 2023 |
| 37217188 | NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial. | Eur Heart J | 2023 |
| 37117140 | Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society. | J Card Fail | 2023 |
| 37051919 | Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis. | Circulation | 2023 |
| 37314801 | Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone. | JAMA Cardiol | 2023 |
| 37448210 | Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: A scientific statement by the Heart Failure Association of the ESC. | Eur J Heart Fail | 2023 |
| 37382961 | Ferric Carboxymaltose in Iron-Deficient Patients with Hospitalized Heart Failure and Reduced Kidney Function. | Clin J Am Soc Nephrol | 2023 |
| 37344038 | Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations. | J Am Coll Cardiol | 2023 |
| 37312239 | Acute heart failure and valvular heart disease: A scientific statement of the Heart Failure Association, the Association for Acute CardioVascular Care and the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. | Eur J Heart Fail | 2023 |
| 37246591 | Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure in elderly patients: A sub-analysis of the STRONG-HF randomized clinical trial. | Eur J Heart Fail | 2023 |
| 37210639 | Prevalence, characteristics and prognostic impact of aortic valve disease in patients with heart failure and reduced, mildly reduced, and preserved ejection fraction: An analysis of the ESC Heart Failure Long-Term Registry. | Eur J Heart Fail | 2023 |
| 37444400 | New Insights in the Era of Clinical Biomarkers as Potential Predictors of Systemic Therapy-Induced Cardiotoxicity in Women with Breast Cancer: A Systematic Review. | Cancers (Basel) | 2023 |
| 37310695 | Erratum. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study. Diabetes Care 2022;45:888-897. | Diabetes Care | 2023 |
| 37278451 | Liver tests, cardiovascular outcomes and effects of empagliflozin in patients with heart failure and preserved ejection fraction: The EMPEROR-Preserved trial. | Eur J Heart Fail | 2023 |
| 37208936 | Worsening of chronic heart failure: definition, epidemiology, management and prevention. A clinical consensus statement by the Heart Failure Association of the European Society of Cardiology. | Eur J Heart Fail | 2023 |